toxylact: a02ac02 calcium silicate antiacids

The first professional lActological database in the word

Calcium silicate (ATC A02AC02) is considered compatible with breastfeeding in usual therapeutic doses, with minimal systemic absorption and no expected adverse effects in the breastfed infant.

Pharmacology and classification

Calcium silicate is an inorganic calcium salt belonging to the ATC group A02A “Antacids”, subgroup A02AC “Calcium compounds,” with the specific code A02AC02. It acts as a weak, locally acting antacid and is also widely used as an excipient and anticaking agent in foods and medicinal products.

In comparison with calcium carbonate, the pharmacologic antacid activity of calcium silicate is lower, and its oral systemic bioavailability is estimated at about 5–8%, versus approximately 15–30% for calcium carbonate. This reduced absorption limits systemic calcium load and lowers the risk of calcium-related adverse outcomes such as milk-alkali syndrome.

Maternal calcium needs and exposure

Published data on daily calcium requirements in lactating women vary widely between populations, reflecting differences in diet and physiology. For example, some community data suggest intakes around 300 mg/day in certain low-intake settings, while recommendations in high‑income countries often approach or exceed 900–1000 mg/day. During lactation, total daily calcium intake from all sources (diet plus supplements/antacids) is generally advised not to exceed about 2.5 g elemental calcium per day.

Calcium silicate may be used both as an active antacid component and as a pharmaceutical excipient in various medicinal products. When used in standard antacid doses within these intake limits, the total maternal calcium burden remains within ranges considered safe for both mother and infant.

Transfer into breast milk and infant exposure

Because calcium silicate is poorly absorbed after oral administration, only a small fraction of ingested calcium enters the maternal circulation and thus becomes available for transfer into breast milk. In controlled observations, therapeutic daily doses of calcium-containing antacids have not substantially altered the calcium concentration in human milk nor adversely affected infant anthropometric development.

Calcium salts, including calcium silicate, are considered compatible with breastfeeding, and routine maternal supplementation does not significantly change milk calcium levels. Safety assessments of calcium silicate as a food additive and anticaking agent indicate low oral toxicity, no evidence of carcinogenicity, reproductive or developmental toxicity, and no genotoxicity, supporting a wide margin of safety for infant exposure via breast milk.

Maternal and infant safety profile

Due to its lower bioavailability, calcium silicate is associated with a reduced risk of milk-alkali syndrome compared with more bioavailable calcium salts, provided usual therapeutic doses are not exceeded. Even if maternal hypercalcemia and a milk‑alkali–like state were to occur before delivery, available data suggest that such metabolic disturbances do not exert mutagenic effects on the infant’s genetic material.

Clinical and guideline experience with antacids in breastfeeding shows that antacids and alginates are considered first‑line and acceptable during lactation, with no need for routine interruption of breastfeeding. Expert lactation resources describe calcium salts as “compatible” and “not risky for breastfeeding or infant,” with no indication to discontinue breastfeeding when used appropriately.

For the breastfed infant, the maximum safe daily calcium intake via all routes is generally considered to be up to about 800 mg of calcium per day, which is well above the incremental contribution from maternal use of calcium silicate at usual doses. No specific adverse reactions in breastfed infants have been attributed to maternal ingestion of calcium silicate–containing antacids.

Toxicological lactation and pregnancy categories

On the basis of current evidence, calcium silicate can be assigned to a very low-risk toxicological lactation category: the substance and/or its metabolites are either not excreted into breast milk in clinically relevant amounts or are not toxic for the breastfed infant at exposures achieved with standard maternal dosing. Breastfeeding does not need to be interrupted or modified when the mother uses calcium silicate–containing products within recommended therapeutic ranges.

Regarding pregnancy, available toxicity studies and regulatory assessments classify calcium silicate as having low acute and chronic toxicity, and it has been used safely as a food additive and pharmaceutical excipient, consistent with a low-risk pregnancy category (e.g. FDA Category A in your local schema). Nonetheless, as with all antacids in pregnancy and lactation, unnecessary chronic high‑dose use should be avoided, and dosing should follow product labeling and clinical guidance.

Practical recommendations for clinical use in lactation

  • Use the lowest effective antacid dose for symptom control and avoid exceeding the total recommended daily calcium intake (approximately 2.5 g elemental calcium/day for the lactating woman).
  • Routine dose and duration of calcium silicate–containing antacids do not warrant any breastfeeding restriction or special monitoring of a healthy, term infant.
  • Consider assessing total calcium burden if the mother is simultaneously using other calcium supplements, vitamin D, thiazide diuretics, or has a history of nephrolithiasis or hyperparathyroidism.
  • In the rare event of maternal symptoms suggestive of hypercalcemia (nausea, vomiting, confusion, polyuria), discontinue calcium-containing products and evaluate promptly, but breastfeeding can generally continue while the underlying metabolic disorder is managed.

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.